Fathi A, Perl A, Fell G, et al. Results from PARADIGM – a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia. Blood 2025;146(Suppl 1):6.

https://doi.org/10.1182/blood-2025-6

ClinicalTrials.gov: NCT04801797

2. VICEROY Study – Aza/Ven/Gilteritinib Triplet (Abstract 654)

Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed FLT3mut+ AML ineligible for intensive induction chemotherapy: Interim results from the phase 1/2 VICEROY study. Blood 2025;146(Suppl 1):654.

ClinicalTrials.gov: NCT05520567

3. Long-Term Follow-Up of Aza/Ven/Gilteritinib in FLT3-Mutated AML (Abstract 45)

Azevedo RS, et al. Long-term follow-up of azacitidine, venetoclax, and gilteritinib in patients with newly diagnosed FLT3-mutated acute myeloid leukemia. Blood 2025;146(Suppl 1):45.

Original publication: Short NJ, Daver N, DiNardo CD, et al. J Clin Oncol 2024;42:1499–1508. https://doi.org/10.1200/JCO.23.01911

ClinicalTrials.gov: NCT04140487

4. PRISM-AML Score (Abstract 453)

Lachowiez CA, et al. Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: A multinational retrospective cohort study. Blood 2025;146(Suppl 1):453.

Interactive Calculator: https://prism-aml.com

5. Additional Studies Referenced in Discussion

•       VIALE-A Trial: DiNardo CD, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 2020;383:617–629. (NCT02993523)

•       VERONA Trial: Randomized study of Aza-Ven vs. Aza vs. placebo in MDS (discussed as a negative study)

•       4-Gene Classifier (mPRS): Bataller A, et al. Prognostic risk signature in patients with AML treated with HMA and venetoclax. Blood Adv 2024;8(4):927–935. https://doi.org/10.1182/bloodadvances.2023011757

•       LACEWING Trial: Azacitidine plus gilteritinib vs. azacitidine plus placebo in FLT3-mutated AML (discussed as a negative study)

Guest: Dr. Carla Casulo, Associate Professor, Wilmot Cancer Centre, University of Rochester

Abstracts Discussed

Follicular Lymphoma

EPCORE-FL1 (Falchi) - Epcoritamab plus lenalidomide-rituximab (R2) in relapsed/refractory FL

Theme: Bispecific antibody combinations in R/R FL; comparing to other approaches

Diffuse Large B-Cell Lymphoma (DLBCL) - Elderly/Unfit Patients

MorningSun (Sharman) - Mosunetuzumab monotherapy in patients ≥80 years or chemo-ineligible

EPCOR-DLBCL-3 (Vitolo) - Epcoritamab monotherapy in elderly patients

R-Pola-Glo - Rituximab-polatuzumab-glofitamab combination in older/frail patients

Theme: Single-agent and combination bispecific strategies for elderly and frail DLBCL patients

DLBCL - First-Line Treatment

SMART STOP (Westin) - Chemotherapy-free approach using lenalidomide, tafasitamab, rituximab, acalabrutinib (ULTRA regimen)

FrontMIND - Tafasitamab-lenalidomide added to R-CHOP

Theme: Chemotherapy-sparing and chemo-intensification strategies in newly diagnosed DLBCL

DLBCL - Relapsed/Refractory

DALY 2-EU (Borchmann) - Dual CD19/CD20 CAR-T (zamto-cel) versus R-GemOx in transplant-ineligible patients

Theme: Expanding CAR-T eligibility; treatment selection in transplant-ineligible R/R DLBCL

Hodgkin Lymphoma

SWOG 1826 - 3-year update: Nivolumab-AVD versus brentuximab-AVD

HD21 - 5-year update: PET-adapted BrECADD versus BEACOPP

Theme: Long-term outcomes and treatment selection in newly diagnosed Hodgkin lymphoma

Burkitt Lymphoma

ZUMA-25 (Van Dorp) - Brexucabtagene autoleucel (Brexu-cel) in relapsed/refractory Burkitt

Theme: CAR-T therapy for the challenging population of R/R Burkitt lymphoma

Mantle Cell Lymphoma - First-Line

TrAVeRse - Acalabrutinib, venetoclax, rituximab

GLOVe - Glofitamab, lenalidomide, venetoclax (high-risk MCL)

BOVen - Zanubrutinib, obinutuzumab, venetoclax (older patients)

MAVO - Acalabrutinib, venetoclax, obinutuzumab

Window-3 - Acalabrutinib-rituximab followed by brexu-cel (high-risk MCL)

Theme: Chemotherapy-free combinations in newly diagnosed mantle cell lymphoma

Episode Highlights 

Main Topics Covered 

1. MajesTEC-3 Trial: Teclistamab-Daratumumab vs. Standard of Care 
   • Trial design and patient population
   • Primary endpoint: Progression-free survival (PFS)
   • MRD negativity rates and depth of response
   • Overall survival and safety profile
   • Clinical implications for treatment selection
2. Treatment Selection in Early Relapse 
   • Comparing MajesTEC-3 and CARTITUDE-4 patient populations
   • Framework for choosing between bispecific antibodies vs. CAR T-cell therapy
   • Managing anti-CD38 exposed patients

Link to the NEJM paper: https://www.nejm.org/doi/abs/10.1056/NEJMoa2514663
 
 

Key Topics Covered

Fundamentals of CMV Management

• Distinguishing CMV reactivation from CMV disease
• Treatment thresholds and target viral loads
• Prophylaxis strategies in non-allograft settings
• Valaciclovir dosing in general hematology populations
• High-risk patient populations

First-Line Therapies

• Valganciclovir: advantages, disadvantages, and myelosuppression
• Foscarnet: indications and monitoring strategies
• Treatment-resistant CMV

Allogeneic Transplant Patients

• High-risk populations and timing of reactivation
• Monitoring protocols post-transplant

Randomized Controlled Trials

AURORA Trial: Maribavir vs. Valganciclovir

• Design: RCT comparing maribavir to valganciclovir for pre-emptive CMV therapy post-allogeneic transplant [https://pubmed.ncbi.nlm.nih.gov/38036487/]

NEJM Letermovir Prophylaxis Trial

• Design: Double-blind, placebo-controlled RCT of letermovir prophylaxis post-allogeneic transplant [https://pubmed.ncbi.nlm.nih.gov/29211658/]

Emerging Patient Populations

• CMV in lymphoma and myeloma patients receiving CAR T-cell therapy and T-cell engaging bispecific antibodies
• Monitoring and prophylaxis strategies for novel immunotherapies
• Impact of CMV on post-CAR T mortality-https://pubmed.ncbi.nlm.nih.gov/40203190/

Topics Covered

1. SMOLDERING MULTIPLE MYELOMA

LINKER-SMM1

Phase 2, open-label study of linvoseltamab monotherapy (200 mg) in patients with high-risk smoldering multiple myeloma by 20/2/20 or PETHEMA criteria, with 2-year treatment duration.

Discussion Points:

• Appropriateness of 2-year treatment duration for precursor condition
• Efficacy and MRD-negative rates
• Safety considerations in asymptomatic population
• Patient selection if available today

2. NEWLY DIAGNOSED MULTIPLE MYELOMA

MajesTEC-5

Phase 2 trial evaluating three teclistamab-daratumumab-based induction regimens in 49 transplant-eligible NDMM patients, followed by auto-transplant and fixed-duration Tec-Dara maintenance.

Discussion Points:

• Post-induction MRD-negativity rates with Tec-DR and Tec-DVR
• Grade 3-5 infection rates and infection-related deaths
• Questionable utility of bortezomib and need for ASCT with 100% MRD-negativity
• High infection prophylaxis requirements

MagnetisMM-6

Phase 1/2 dose-finding study of fixed-dose elranatamab 76 mg Q4W with Dara-Len in 37 transplant-ineligible NDMM patients (median age 75 years).

Discussion Points:

• VGPR or better rates
• Safety profile including infections and CRS/ICANS
• Risk of continuous therapy in elderly/frail population

LINKER-MM4

Phase 1/2 study of linvoseltamab monotherapy in NDMM with both transplant-eligible and transplant-ineligible pathways, exploring three dose levels (50, 100, 200 mg).

Discussion Points:

• Efficacy of single-agent Linvo in NDMM
• Whether any NDMM population could achieve long-term control with single-agent BCMA BsAb
• Safety profile

3. RELAPSED/REFRACTORY MULTIPLE MYELOMA

CAMMA-1

Phase 1b randomized dose-expansion study of cevostamab (FcRH5×CD3 bispecific) combined with pomalidomide-dexamethasone in BCMA-naïve patients with median 2 prior lines of therapy.

Discussion Points:

• Efficacy and safety results
• Positioning in treatment paradigm
• Use before BCMA BsAbs?

Sonrotoclax + Dexamethasone in t(11;14) R/R MM

Phase 1/2 study of sonrotoclax (next-generation BCL2 inhibitor) plus dexamethasone as an all-oral regimen in patients with t(11;14) R/R MM (median 3 prior lines, ~75% triple-exposed).

Discussion Points:

• Efficacy including response rate and PFS
• Safety profile
• Future of BCL2 inhibitors in t(11;14) myeloma in the era of BsAbs and CAR T

RedirecTT-1

Phase 2 trial combining teclistamab + talquetamab in 90 heavily pretreated patients with R/R extraosseous extramedullary disease (84% triple-class refractory, 36% penta-refractory, 20% prior BCMA CAR T).

Discussion Points:

• Response rate and durability in difficult-to-treat population
• Safety concerns with dual bispecific combination
• Off-label use considerations

4. CAR T-CELL THERAPY TOXICITIES

CAR T Immune-Related Adverse Events (UPenn Study - Ho et al)

Large cohort study of 198 patients (125 cilta-cel, 73 ide-cel) examining all adverse events other than CRS, ICANS, IEC-HS, and IECAHT.

Discussion Points:

• Landscape of CAR T IRAEs: incidence, types, and timing
• Risk factors identified for CirAEs
• Mechanism of toxicities and role of CD4+ CAR T-cells
• Clinical implications: Should prophylactic corticosteroids be used? What ALC threshold? Optimal dose/duration? Prospective studies needed?

Key Discussion Topics

1. Genetic Heterogeneity in B-Cell Lymphomas

Complex genetic landscape of DLBCL

Implications for treatment strategies

Need for personalized approaches

2. Clinical Need for ctDNA in Lymphoma

Why ctDNA is needed in aggressive lymphomas:

Curative vs. non-curative treatment settings

Limitations of current PET imaging

Additional prognostic information beyond imaging

Risk stratification capabilities

Potential to avoid overtreatment

Therapy adaptation opportunities

3. Challenges in Lymphoma MRD Assessment

Why lymphoma MRD is more complex than other hematologic malignancies:

Differences from acute leukemias, CLL, and myeloma

Technical challenges specific to lymphoid tumors

Lower circulating tumor burden compared to liquid tumors

4. ClonoSEQ Technology

Mechanism: Immunoglobulin sequencing approach

Advantages: Established platform with regulatory approval

Disadvantages: Limited sensitivity in peripheral blood, requires adequate tumor sample

5. CAPP-Seq Technology

Full Name: Cancer Personalized Profiling by Deep Sequencing

Innovation: Developed ~10 years ago by Dr. Alizadeh's group

Mechanism: Targeted sequencing of cancer-specific mutations

Advantages: High sensitivity, personalized approach

6. PhasED-Seq Technology

Evolution: Next-generation advancement of CAPP-Seq

Key Improvements: Enhanced sensitivity and specificity

Technical Advances: Phased variant detection

Clinical Data Highlights

1. Remission Assessment by ctDNA in LBCL on 5 prospective studies of frontline anthracycline-based chemo-immunotherapy: https://pubmed.ncbi.nlm.nih.gov/40802906/

2. Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from HOVON-902 clinical trial: https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.7000

3. Korean data on prognostic utility of ctDNA: https://ashpublications.org/blood/article/142/Supplement%201/69/501573

Key Clinical Trials Discussed

1. POLARGO Trial - Polatuzumab + R-GemOx vs R-GemOx in R/R DLBCL

2. SUNMO Trial - Mosunetuzumab + Polatuzumab vs R-GemOx in R/R DLBCL

3. STARGLO Trial - Glofitamab + GemOx vs R-GemOx in R/R DLBCL (2-Year Update)

4. EPCORE NHL-5 & NHL-7 - Epcoritamab Combinations in Frontline DLBCL

5. EPCOR-RICE - Epcoritamab + R-ICE in Transplant-Eligible R/R DLBCL

6. LOTIS-7 Trial - Loncastuximab + Glofitamab in R/R DLBCL

7. Additional Studies Mentioned:

R-Pola-Glo Frail Study

DLBCL Classification

1. Relevance of Bone Marrow Biopsy in Follicular Lymphoma: https://pubmed.ncbi.nlm.nih.gov/35787017/

2. TROG 99.03 (RCT of Systemic Therapy after Involved-Field Radiotherapy in Patients with Early-Stage Follicular Lymphoma): https://pubmed.ncbi.nlm.nih.gov/29975623/

3. Long-term follow-up results of RCT comparing early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumor burden follicular lymphoma: https://pubmed.ncbi.nlm.nih.gov/40306831/

4. RELEVANCE RCT: Lenalidomide plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma: https://ascopubs.org/doi/10.1200/JCO.22.00843

5. GALLIUM RCT: Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL. https://pubmed.ncbi.nlm.nih.gov/37404773/

https://pubmed.ncbi.nlm.nih.gov/28976863/

6. Long-term follow-up of mosunetuzumab in relapsed/refractory FL: 

https://pubmed.ncbi.nlm.nih.gov/39447094/

7. Epcoritamab in relapsed/refractory FL: https://pubmed.ncbi.nlm.nih.gov/38889737/

8. Phase 3 inMIND RCT: Tafasitamab plus Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma: https://ashpublications.org/blood/article/144/Supplement%202/LBA-1/534319

9. Long term follow-up results from the Phase 3 PRIMA trial of rituximab maintenance in Follicular Lymphoma: https://ascopubs.org/doi/10.1200/JCO.19.01073

• ELN 2022 AML Classification https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022
• Predictors of outcomes in adults with AML and KMT2A rearrangements: https://www.nature.com/articles/s41408-021-00557-6
• DOT1L inhibitor https://ashpublications.org/blood/article/131/24/2661/37193/The-DOT1L-inhibitor-pinometostat-reduces-H3K79
• AUGMENT 101: https://ascopubs.org/doi/10.1200/JCO.24.00826
• Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study: https://ashpublications.org/blood/article/doi/10.1182/blood.2025028357/537139/Menin-inhibition-with-revumenib-for-NPM1-mutated
• KOMET-001: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00386-3/abstract
• SAVE trial: https://ashpublications.org/blood/article/144/Supplement%201/216/530724/Phase-I-II-Study-of-the-All-Oral-Combination-of
• KOMET-007: https://library.ehaweb.org/eha/2025/eha2025-congress/4159213/harry.erba.ziftomenib.combined.with.intensive.induction.chemotherapy.2872B329.in.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2882%2Aot_id%3D31560%2Amarker%3D5843%2Afeatured%3D19595
• MEN1 mutations: https://www.nature.com/articles/s41586-023-05755-9

https://www.fda.gov/advisory-committees/advisory-committee-calendar/may-20-21-2025-meeting-oncologic-drugs-advisory-committee-05202025#event-materials

Here is the youtube link for FDA proceedings: 

https://www.youtube.com/watch?v=5ecyDbK9ezc

• Midostaurin https://www.nejm.org/doi/10.1056/NEJMoa1513098?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov
• Avapritinib
• EXLPORER study: https://www.nature.com/articles/s41591-021-01538-9
• PATHFINDER study: https://www.nature.com/articles/s41591-021-01539-8
• Bezuclastinib: APEX trial: https://ashpublications.org/blood/article/144/Supplement%201/659/530240/Apex-Part-1-Updated-Assessment-of-Bezuclastinib
• HSCT for Advanced SM: https://ascopubs.org/doi/10.1200/JCO.2014.55.2018

1. CTTLN cases from CARTITUDE-4: https://pubmed.ncbi.nlm.nih.gov/39938094/

2. CTTLN case from MSKCC with insertional mutagenesis: https://pubmed.ncbi.nlm.nih.gov/39908432/

3. Other CTTLN cases in myeloma:
https://pubmed.ncbi.nlm.nih.gov/38865661/
https://pmc.ncbi.nlm.nih.gov/articles/PMC8417502/

4. Response and resistance to menin inhibitors in UBTF tandem duplication AML: https://pubmed.ncbi.nlm.nih.gov/38924737/

Older AML: Ven+HMA vs 7+3

Abstract 450: https://ash.confex.com/ash/2024/webprogram/Paper210320.html

Abstract 971: https://ash.confex.com/ash/2024/webprogram/Paper202801.html

Abstract 969: https://ash.confex.com/ash/2024/webprogram/Paper199267.html

Venetoclax resistance mechanisms

https://pubmed.ncbi.nlm.nih.gov/39478230/

FLAG-GO vs FLAG-IDA 

https://ashpublications.org/blood/article/144/Supplement%201/1513/532742/Gemtuzumab-Ozogamicin-Added-to-Fludarabine

 CPX-351: 

Abstract 55: https://ash.confex.com/ash/2024/webprogram/Paper207094.html

Abstract 60: https://ash.confex.com/ash/2024/webprogram/Paper200413.html

Menin Inhibitors 

Abstract 211 https://ash.confex.com/ash/2024/webprogram/Paper194384.html

Abstract 212 https://ash.confex.com/ash/2024/webprogram/Paper207106.html

Abstract 213 https://ash.confex.com/ash/2024/webprogram/Paper194827.html

Abstracts 214 https://ash.confex.com/ash/2024/webprogram/Paper198218.html

Abstract 215 https://ash.confex.com/ash/2024/webprogram/Paper198218.html

Abstract 216 https://ash.confex.com/ash/2024/webprogram/Paper204375.html

FLT3 inhibitors
Abstract 221: https://ash.confex.com/ash/2024/webprogram/Paper201595.html

MDS

 Abstract 349: https://ash.confex.com/ash/2024/webprogram/Paper194510.html

ATRA in MDS:  

https://ash.confex.com/ash/2024/webprogram/Paper200433.html 

1. ASC4FIRST RCT: Asciminib in newly diagnosed CML. 

https://pubmed.ncbi.nlm.nih.gov/38820078/

2. 5-year follow-up of ENESTnd RCT (nilotinib): 

https://pubmed.ncbi.nlm.nih.gov/26837842/

3. 10-year follow-up of ENESTnd RCT (nilotinib): 

https://pubmed.ncbi.nlm.nih.gov/33414482/

4. 10-year follow-up of CML-IV RCT (imatinib): 

https://pubmed.ncbi.nlm.nih.gov/25676422/

5. MD Anderson data on low-dose dasatinib (50 mg): 

https://pubmed.ncbi.nlm.nih.gov/36054032/

https://pubmed.ncbi.nlm.nih.gov/31553487/

6. CML: 2025 update on diagnosis, therapy, and monitoring: 

https://pubmed.ncbi.nlm.nih.gov/39093014/

1. AQUILA Trial in High-Risk SMM

• Overview of the AQUILA trial testing single-agent daratumumab for high-risk smoldering multiple myeloma (HR-SMM) versus active monitoring.
•  Discussion on patient characteristics, primary endpoints, and results showing significant progression-free survival (PFS) benefit with Dara.
•  Insights into modes of progression, adequacy of active surveillance, and post-protocol therapy in control arm.
•  Read the abstract.
•  Read the simultaneous publication at NEJM. 

2. Anito-Cel: New BCMA CAR T Therapy

•  Early data from the iMMagine-1 trial showing strong efficacy and a promising safety profile for Anito-Cel, a novel BCMA CAR T.
•  Discussion of its potential to rival cilta-cel while avoiding neurotoxicity concerns.
•  Read the abstract.

3. CARTITUDE-4 Update

•  Updates on MRD-negativity rates and survival outcomes for cilta-cel in relapsed myeloma, with significant benefits over standard care.
•  Read the abstract.

4. ANDROMEDA OS Data in AL Amyloidosis

•  Long-term data showing an overall survival (OS) benefit of Dara-VCd over VCd in AL amyloidosis.
•  Insights into cardiac responses and crossover impact.
•  Read the abstract.

5. OPTIMUM Trial in Ultra-High-Risk NDMM

• Five-year follow-up of a tailored approach for ultra-high-risk newly diagnosed myeloma patients with continuous therapy incorporating multiple active agents. 
• Subgroup outcomes highlighting both challenges and exceptional results.
•  Read the abstract

6. GMMG-HD7 Trial PFS Update

•  Phase 3 trial results on Isa-VRD vs. VRD induction and risk-adapted tandem ASCT.
•  Discussion on the role of CD38 in maintenance therapy.
•  Read the abstract
•  Read the simultaneous publication at JCO

7. Exciting New Drugs

•  Review of three innovative therapies: inobrodib, a BCMA-CD38 trispecific antibody, and cevostamab, a FcRH5-targeted bispecific antibody.
•  Expert insights into their efficacy and potential to reshape myeloma care.
•  Read the abstract

1. 3 RCTs in Mantle Cell Lymphoma: 

a) Update on TRIANGLE: https://ash.confex.com/ash/2024/webprogram/Paper200735.html

b) ENRICH Trial (Continuous Ibrutinib-Rituximab vs CIT [R-CHOP or BR]): https://ash.confex.com/ash/2024/webprogram/Paper199710.html

c) ECOG-ACRIN EA4151 Trial (Auto-HCT vs Rituximab maintenance alone in patients with undetectable MRD after induction): https://ash.confex.com/ash/2024/webprogram/Paper212973.html

2. DLBCL: 

a) Update on POLARIX Trial: https://ash.confex.com/ash/2024/webprogram/Paper197938.html

b) Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in DLBCL Patients Receiving Polatuzumab Vedotin: https://ash.confex.com/ash/2024/webprogram/Paper202153.html

c) COALITION trial: https://ash.confex.com/ash/2024/webprogram/Paper204930.html

3. Follicular Lymphoma: 

a) Phase 3 inMIND trial (Tafasitamab + R2 vs Placebo + R2): https://ash.confex.com/ash/2024/webprogram/Paper212970.html

b) Loncastuximab tesirine with rituximab in patients with R/R FL: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00345-4/abstract

4. CLL: 

a) AMPLIFY Trial (Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy in 1st line CLL): https://ash.confex.com/ash/2024/webprogram/Paper200701.html

5. Hodgkin Lymphoma: 

a) Pembrolizumab Maintenance Instead of Auto-HCT for R/R HL: https://ash.confex.com/ash/2024/webprogram/Paper202537.html

1. DREAMM-7 RCT: Belantamab-Vd vs Daratumumab-Vd in relapsed MM. https://pubmed.ncbi.nlm.nih.gov/38828933/

2. DREAMM-8 RCT: Belantamab-Pd vs PVd in relapsed MM. https://pubmed.ncbi.nlm.nih.gov/38828951/

3. Long-term follow-up of CASSIOPEIA Trial: https://pubmed.ncbi.nlm.nih.gov/38889735/

4. Update on MRD data from PERSEUS Trial: https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.7502

1. Comparison of ABVD versus Stanford V in older Hodgkin Lymphoma patients: https://pmc.ncbi.nlm.nih.gov/articles/PMC3906856/

2. Outcome of older adults ECHELON-1: https://pubmed.ncbi.nlm.nih.gov/34162178/

3. Sequential BV-AVD in older adults with Hodgkin Lymphoma: https://pubmed.ncbi.nlm.nih.gov/30179569/

4. SWOG S1826 trial (Nivo-AVD vs AAVD in advanced stage classical HL): https://pubmed.ncbi.nlm.nih.gov/39413375/

5. S1826 outcomes in older adults: https://ash.confex.com/ash/2023/webprogram/Paper180114.html

6. Single-agent BV for older adults with Hodgkin: https://ashpublications.org/blood/article/142/Supplement%201/4435/503453

1. VIALE-A study: https://www.nejm.org/doi/full/10.1056/NEJMoa2012971

2. 10 day Decitabine plus venetoclax for ND AML https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(20)30210-6/abstract

3. Genetic Risk Stratification and Outcomes with AML treated with venetoclax and azacitidine https://ashpublications-org.proxy.library.vanderbilt.edu/blood/article/doi/10.1182/blood.2024024944/517355/Genetic-Risk-Stratification-and-Outcomes-Among

4. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations https://ashpublications-org.proxy.library.vanderbilt.edu/blood/article/doi/10.1182/blood.2024025409/517356/Genetic-risk-classification-for-adults-with-AML

5. AGILE study: Ivosidenib and azacitidine in IDH1-mutated AML https://www.nejm.org/doi/full/10.1056/NEJMoa2117344

6. MRD response and prognosis in treatment naïve AML with AZA/VEN https://ascopubs.org/doi/10.1200/JCO.21.01546?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

7. Monocytic subclone confer resistance to venetoclax-based therapy in patients with AML https://aacrjournals.org/cancerdiscovery/article/10/4/536/2403/Monocytic-Subclones-Confer-Resistance-to

8. VEN/DEC vs 7+3 https://ashpublications.org/blood/article/142/Supplement%201/970/503790/Comparing-the-Efficacy-and-Safety-of-Venetoclax

9. FILO study: Outcomes of AML  https://onlinelibrary.wiley.com/doi/10.1002/ajh.27417

10. Treatment-free remission after ceasing venetoclax-based therapy in patients with AML https://ashpublications-org.proxy.library.vanderbilt.edu/bloodadvances/article/6/13/3879/485175/Treatment-free-remission-after-ceasing-venetoclax

11. Targeting molecular MRD and low-blast relapse in AML with Venetoclax and LDAC (VALDAC) https://ascopubs-org.proxy.library.vanderbilt.edu/doi/10.1200/JCO.23.01599?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

12. INTERCEPT trial: https://ashpublications.org/blood/article/140/Supplement%201/3341/492722/ALLG-AMLM26-Phase-1B-2-Study-Investigating-Novel

Here are the key papers we discussed: 

1. MAIA trial (Daratumumab-Lenalidomide-Dexamethasone [DRd] vs Rd in newly diagnosed transplant ineligible myeloma): https://pubmed.ncbi.nlm.nih.gov/34655533/

2. S0777 trial (VRd vs Rd in newly diagnosed myeloma [transplant-ineligible or transplant-deferred]): https://pubmed.ncbi.nlm.nih.gov/32393732/

3. IMROZ trial (Isatuximab-VRd vs VRd in newly diagnosed transplant-ineligible myeloma): https://pubmed.ncbi.nlm.nih.gov/38832972/

4. IFM-2020/BENEFIT trial (Isatuximab-VRd vs Isatuximab-Rd in newly diagnosed transplant-ineligible myeloma): https://pubmed.ncbi.nlm.nih.gov/38830994/

5. GEM2017FIT trial (VMP-Rd vs KRd vs Dara-KRd in newly diagnosed transplant-ineligible myeloma): https://ashpublications.org/blood/article/142/Supplement%201/209/500199

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042664/ 

2. MEDALIST trial: Luspatercept

https://www.nejm.org/doi/10.1056/NEJMoa1908892?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed 

3. COMMANDS trial : Luspatercept 

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00874-7/abstract

https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00203-5/abstract 

4. IMerge trial: Imetelstat 

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01724-5/abstract

1.     MIPS PV scoring system

https://pubmed.ncbi.nlm.nih.gov/31945802/

2.     REVEAL study

https://ashpublications.org/blood/article/143/16/1646/506717/Association-between-elevated-white-blood-cell

3.     MAJIC PV study

https://ascopubs.org/doi/10.1200/JCO.22.01935?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

4.     Cyto-PV Study

https://www.nejm.org/doi/full/10.1056/NEJMoa1208500

5.     PROUD-PV and CONTINUATION-PV trials

https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(19)30236-4/abstract

6.     RESPONSE clinical trial

https://www.nejm.org/doi/full/10.1056/NEJMoa1409002

7.     Rusferitide in PV

https://www.nejm.org/doi/10.1056/NEJMoa2308809?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

1.      STARGLO: Glofit-GEMOX vs R-GEMOX in relapsed/refractory DLBCL

https://library.ehaweb.org/eha/2024/eha2024-congress/4136516

2.     Epco-Pola-R-CHP for 1st line DLBCL (EPCORE NHL-5 study):

https://library.ehaweb.org/eha/2024/eha2024-congress/422343

3.     3-year follow-up of TRANSFORM (Liso-Cel vs CITàASCT in R/R DLBCL): https://meetings.asco.org/abstracts-presentations/232740

4.     ECHO RCT: Acalabrutinib-BR vs Placebo-BR in previously untreated elderly MCL: https://library.ehaweb.org/eha/2024/eha2024-congress/4136515

5.     HD21: escBEACOPP vs BrECADD in 1st line classical HL: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01315-1/fulltext

6.     Combination pirtobrutinib, venetoclax, and obinutuzumab in 1st line CLL: https://library.ehaweb.org/eha/2024/eha2024-congress/422268

7.      Single-agent epcoritamab in Richter’s transformation: EPCORE CLL-1: https://library.ehaweb.org/eha/2024/eha2024-congress/422267

1.      Recording of FDA ODAC meeting: https://www.youtube.com/watch?v=pooME9gMaL0

2.     EVIDENCE meta-analysis on individual-level and trial-level correlation between MRD and PFS/OS in multiple myeloma: https://pubmed.ncbi.nlm.nih.gov/38768337/

3.     Predictors of un-sustained MRD-negativity in multiple myeloma: 

a)     Secondary analysis of FORTE trial: https://pubmed.ncbi.nlm.nih.gov/38048557/

b)     Secondary analysis of GEM2012MENOS65 and GEM2014MAIN trials: https://pubmed.ncbi.nlm.nih.gov/38048552/

4.     Kinetics of MRD resurgence and subsequent relapse in multiple myeloma: https://pubmed.ncbi.nlm.nih.gov/34807986/

5.     MRD2STOP trial (MRD-guided maintenance discontinuation): https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.106

6.     MRD-guided maintenance discontinuation in myeloma (Secondary analysis of GEM2012MENOS65 trial): https://pubmed.ncbi.nlm.nih.gov/37506339/

·       GIPSS: Genetically inspired prognostic scoring system that is exclusively based on genetic markers.

§  https://www.nature.com/articles/s41375-018-0107-z

·       MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis

§  https://ascopubs.org/doi/10.1200/JCO.2018.78.9867?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

·       TRANSFORM-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis

§  https://ashpublications.org/blood/article/142/Supplement%201/620/502738/Transform-1-A-Randomized-Double-Blind-Placebo

·       MANIFEST-2: Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study

§  https://ashpublications.org/blood/article/142/Supplement%201/628/502728/Pelabresib-in-Combination-with-Ruxolitinib-for

·       XPORT-MF-034: Selinexor Plus Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Patients with Myelofibrosis: Long Term Follow up from XPORT-MF-034 Suggestive of Disease Modification

1. Meta-analysis of individual patient-level data from CALGB, IFM, and Italian maintenance RCTs (lenalidomide vs placebo or observation): 

https://pubmed.ncbi.nlm.nih.gov/28742454/

2. Myeloma XI RCT (lenalidomide vs observation): https://pubmed.ncbi.nlm.nih.gov/30559051/

3. Outcomes of lenalidomide maintenance stratified by cytogenetic subgroups (Secondary analysis of Myeloma XI): https://pubmed.ncbi.nlm.nih.gov/36564045/

4. Canadian real-world data on lenalidomide maintenance: https://pubmed.ncbi.nlm.nih.gov/33054120/

5. FORTE trial (Carfilzomib-Lenalidomide vs Lenalidomide): https://pubmed.ncbi.nlm.nih.gov/34774221/

6. ATLAS trial (Carfilzomib-Lenalidomide-Dexamethasone vs Lenalidomide): https://pubmed.ncbi.nlm.nih.gov/36642080/

7. Differential censoring and potential impact on PFS in ATLAS trial: https://pubmed.ncbi.nlm.nih.gov/37433885/

8. GEM2014 (Ixazomib-Lenalidomide-Dexamethasone vs Lenalidomide-Dexamethasone): https://ashpublications.org/blood/article-abstract/142/18/1518/497188

9. MASTER trial (MRD-guided treatment de-escalation): https://pubmed.ncbi.nlm.nih.gov/37776872/

10. Outcomes after MRD-guided treatment discontinuation (Secondary analysis of GEM2014MAIN trial): https://pubmed.ncbi.nlm.nih.gov/37506339/

·        Very low risk: No prior thrombosis, age ≤60 years, JAK2-unmutated

·        Low risk: No prior thrombosis, age ≤60 years, JAK2-mutated

·        Intermediate risk: No thrombosis, age >60 years, JAK2-unmutated

·        High risk: History of thrombosis (any age/genotype), or age >60 years with JAK2 mutation

https://ashpublications.org/blood/article/120/26/5128/30914/Development-and-validation-of-an-International

2.    The MIPSS-ET provides points for:

·        Age > 60 years (3 points)

·        Adverse mutation (SF3B1/SRSF2/U2AF1/TP53) (2 points)

·        Male sex (1 point)

·        White blood cell count ≥11 × 10^9/L (1 point)

·        https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.16380?sid=nlm%3Apubmed

3.    Aspirin

o   Is there a benefit of twice-daily aspirin dosing, especially in high-risk or JAK2-mutant disease?

https://ashpublications.org/blood/article/136/2/171/454293/A-randomized-double-blind-trial-of-3-aspirin

4.     Cytoreduction in High-risk ET
 

Hydroxyurea: https://www.nejm.org/doi/full/10.1056/NEJM199504273321704

Pegylated interferon alfa

MPD-RC 112 Mascarenhas J et al. A randomized phase 3 trial of interferon- α vs hydroxyurea in polycythemia vera and essential thrombocythemia. Blood . 2022) 

https://ashpublications.org/blood/article/139/19/2931/483404/A-randomized-phase-3-trial-of-interferon-vs

Anagrelide in ET

https://ashpublications.org/blood/article/121/10/1720/31186/Anagrelide-compared-with-hydroxyurea-in-WHO

5.    Ruxolitinib  

In a randomized study phase 2 study (MAJIC-ET), ruxolitinib treatment did not deliver better rates of hematological response than best-available therapy, although symptoms did improve. 

·        MAJIC-ET study which is a randomized phase 2 trial 

·        ET patients resistant/intolerant to HU were randomized to receive RUX or standard treatment (HU 71%, anagrelide 48%, IFN 40%). The primary study outcome was CR, defined by normal platelet and white cell counts and normal spleen size.  

·        At 1 year, response was achieved in 46% of patients in the RUX group and in 44% in the standard arm, without statistically significant difference between the two groups.  

·        In addition, no difference was observed in the rates of thrombosis, hemorrhage, and disease transformation after 2 years of follow-up.  

·        MRs were also uncommon. RUX was superior, however, in symptom control. 

https://ashpublications.org/blood/article/130/17/1889/36509/Ruxolitinib-vs-best-available-therapy-for-ET

RCTs of BCMA CAR T-cell Therapy in Early Relapsed Multiple Myeloma:

a) KarMMa-3 (ide-cel): https://pubmed.ncbi.nlm.nih.gov/36762851/

b) CARTITUDE-4 (cilta-cel): https://pubmed.ncbi.nlm.nih.gov/37272512/

FDA ODAC on overall survival data from KarMMa-3 and CARTITUDE-4:
https://www.youtube.com/watch?v=VSjdGeeXb40

Here are the key articles discussed:

1.      Optimal use of tissue biopsy in AL amyloidosis: https://pubmed.ncbi.nlm.nih.gov/28271734/

2.     Mayo 2004 staging:  https://pubmed.ncbi.nlm.nih.gov/15365071/

3.     Mayo 2012 staging: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3675680/

4.     Renal staging: https://pubmed.ncbi.nlm.nih.gov/25115890/

5.     Hematologic and cardiac response criteria in AL amyloidosis: https://pubmed.ncbi.nlm.nih.gov/23091105/

6.     ANDROMEDA Trial: Dara-VCD vs VCD in newly diagnosed AL amyloidosis: https://pubmed.ncbi.nlm.nih.gov/34192431/

7.      How I Treat AL Amyloidosis: https://pubmed.ncbi.nlm.nih.gov/34517412/

8.     Venetoclax in AL amyloidosis (largest retrospective study till date): 

https://pubmed.ncbi.nlm.nih.gov/33431806/

1. TRANSFORM-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis

https://ash.confex.com/ash/2023/webprogram/Paper173509.html

2. MANIFEST-2: Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study

https://ash.confex.com/ash/2023/webprogram/Paper179141.html

3. Venetoclax + Decitabine vs 7+3 in AML

https://ashpublications.org/blood/article/142/Supplement%201/970/503790/Comparing-the-Efficacy-and-Safety-of-Venetoclax

4. FILO study: Acute Myeloid Leukemia Patients Who Stopped Venetoclax or/and Azacytidine for Other Reasons Than Progression Have a Prolonged Treatment Free Remission and Overall Survival. 

https://ash.confex.com/ash/2023/webprogram/Paper185437.html 

5. AUGMENT-101: Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results

https://ash.confex.com/ash/2023/webprogram/Paper172422.html

6. VEN+HMA in HR MDS: Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study

https://ash.confex.com/ash/2020/webprogram/Paper139492.html

Here are the key trials we discussed:

1. BMT CTN 1203 trial: Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of GVHD in allogeneic transplantation.

https://pubmed.ncbi.nlm.nih.gov/30824040/

2. BMT CTN 1703 study: Post-Transplantation Cyclophosphamide-Based GVHD prophylaxis 

https://pubmed.ncbi.nlm.nih.gov/37342922/

3. Patient-Reported Outcomes of BMT CTN 1703

https://ash.confex.com/ash/2023/webprogram/Paper187859.html

4. Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil

https://pubmed.ncbi.nlm.nih.gov/37311510/

5. BMT CTN 1301 trial: Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies

https://pubmed.ncbi.nlm.nih.gov/34855460/

6. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD (ABA2)

https://pubmed.ncbi.nlm.nih.gov/33449816/

7. Aurora Kinase a Inhibition for Gvhd and Relapse Prevention after Allogeneic HCT: Phase I Trial in Combination with Ptcy/Sirolimus

https://ash.confex.com/ash/2023/webprogram/Paper181292.html

First, we will focus on a few abstracts in precursor states, MGUS. 

1.      New diagnostic criteria for light chain MGUS (IStopMM): 

             https://ash.confex.com/ash/2023/webprogram/Paper188547.html

             https://ash.confex.com/ash/2023/webprogram/Paper182661.html

2.     PERSEUS Trial-Dara-VRD vs VRD in newly diagnosed transplant-eligible myeloma: 

https://ash.confex.com/ash/2023/webprogram/Paper191911.html

3.     ISKIA trial: Isa-KRD vs KRD in newly diagnosed transplant-eligible myeloma:

 https://ash.confex.com/ash/2023/webprogram/Paper177546.html

4.     Phase 1/2 study for Daratumumab-Venetoclax-Dexamethasone in early relapsed t(11;14) myeloma:

https://ash.confex.com/ash/2023/webprogram/Paper180766.html

5.     GMMG Relapse Trial (Long-term follow-up data from randomized controlled trial of salvage transplant in myeloma)

 
https://ash.confex.com/ash/2023/webprogram/Paper178835.html

6.     Overall survival results of KarMMa-3 trial

https://ash.confex.com/ash/2023/webprogram/Paper178933.html

7.      GEM2017FIT Trial: Dara-KRd vs KRd vs VMP-RD in non-transplant eligible patients:

https://ash.confex.com/ash/2023/webprogram/Paper179866.html

Here are the abstracts that were discussed:

Mantle Cell Lymphoma

1. BOVen trial-A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Treatment-Naïve, TP53-Mutant Mantle Cell Lymphoma

https://ash.confex.com/ash/2023/webprogram/Paper180069.html

2. SYMPATICO Trial: Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma (Late Breaking Abstract)

 https://ash.confex.com/ash/2023/webprogram/Paper191921.html

Chronic Lymphocytic Leukemia

1. FLAIR trial: Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

Link for simultaneous NEJM publication: https://www.nejm.org/doi/10.1056/NEJMoa2310063

2. Ibrutinib retreatment in Phase 2 CAPTIVATE study:

https://ash.confex.com/ash/2023/webprogram/Paper187128.html

Hodgkin Lymphoma
 

1. S1826 outcomes in older adults: 

https://ash.confex.com/ash/2023/webprogram/Paper180114.html

Diffuse Large B-cell Lymphoma

1. Smart STOP study: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma

https://ash.confex.com/ash/2023/webprogram/Paper180381.html

2. Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

https://ash.confex.com/ash/2023/webprogram/Paper177588.html

1. Glofitamab for Relapsed/Refractory DLBCL:

https://pubmed.ncbi.nlm.nih.gov/36507690/

2. Long-term follow-up data on blinatumomab in relapsed/refractory B-cell NHL:

https://pubmed.ncbi.nlm.nih.gov/31451445/

3. Phase 1/2 study of epcoritamab in relapsed/refractory DLBCL:

https://pubmed.ncbi.nlm.nih.gov/36548927/

4. Phase 2 trial of mosunetuzumab in relapsed/refractory follicular lymphoma:

https://pubmed.ncbi.nlm.nih.gov/35803286/

5. Phase 1 trial of odronextamab in relapsed/refractory B-cell NHL:

https://pubmed.ncbi.nlm.nih.gov/35366963/

6. Epcoritamab + R2 in high-risk follicular lymphoma:

https://meetings.asco.org/abstracts-presentations/218265

7. Glofitamab in Mantle Cell Lymphoma:

https://ashpublications.org/blood/article/140/Supplement%201/178/489039

https://www.nejm.org/doi/full/10.1056/nejmoa1507471

2. RATIFY study: Midostaurin plus chemotherapy for AML with a FLT3 mutation

https://www.nejm.org/doi/full/10.1056/nejmoa1614359

3. QuANTUM-First trial: Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00464-6/fulltext

4. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups

https://ashpublications.org/blood/article/127/12/1551/35035/Benefit-of-high-dose-daunorubicin-in-AML-induction

5. Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia

https://ascopubs.org/doi/10.1200/JCO.2017.72.8618?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

6. Phase 3 trial of gilteritinib plus azacitidine vs. azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy

https://ashpublications.org/blood/article/140/17/1845/486088/Phase-3-trial-of-gilteritinib-plus-azacitidine-vs

7. ADMIRAL: Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML

https://www.nejm.org/doi/full/10.1056/nejmoa1902688

8. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia

https://ascopubs.org/doi/10.1200/JCO.22.00602?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

9. Levis MJ, Hamadani M, Logan B, et al: BMT-CTN 1506 (MORPHO): A randomized trial of the FLT3 inhibitor gilteritinib as post-transplant maintenance for FLT3-ITD AML. EHA 2023 Hybrid Congress. Abstract LB2711. Presented June 11, 2023.

10. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial 

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30455-1/fulltext?dgcid=raven_jbs_etoc_email

Here are the shownotes:

1. Excellent tweetorial thread by Dr. Fonseca highlighting some of the historical studies that identified t(11;14) and its prognostic impact in myeloma: 

https://x.com/Rfonsi1/status/1206004966294294528?s=20

2. Natural history of t(11;14) myeloma in the era of PIs and IMiDs:

https://pubmed.ncbi.nlm.nih.gov/28655925/

3. BELLINI trial (Ven-Bort-Dex vs Bort-Dex in all-comers):

https://pubmed.ncbi.nlm.nih.gov/33129376/

4. Efficacy of Dara-VCD by cytogenetic subgroups in AL Amyloidosis:

https://pubmed.ncbi.nlm.nih.gov/36779691/

5. CANOVA Trial (Ven-Dex vs Pom-Dex in t[11;14]):

https://www.clinical-lymphoma-myeloma-leukemia.com/issue/S2152-2650(23)X0011-1?pageStart=0

6. Phase 1/2 trial on Daratumumab-Venetoclax-Dex in Relapsed/Refractory Myeloma:

https://pubmed.ncbi.nlm.nih.gov/34388020/

7. Phase 1/2 trial on Venetoclax-Carfilzomib-Dex in relapsed/refractory myeloma:

https://pubmed.ncbi.nlm.nih.gov/34470049/

1. ASH 2022 data on PET scan in CNS lymphoma - https://ashpublications.org/blood/article/140/Supplement%201/1334/492207/Is-It-Possible-to-Omit-Bone-Marrow-Biopsy-in?searchresult=1 

2. Elizabeth Schorb ASH 2022 (MARTA) 65-80 year olds – https://ashpublications.org/blood/article/140/Supplement%201/1773/493224/High-Dose-Chemotherapy-and-Autologous-Stem-Cell?searchresult=1 

3. IESLG 32 study (MATRIX) - https://pubmed.ncbi.nlm.nih.gov/27132696/ and https://pubmed.ncbi.nlm.nih.gov/35562406/ 

4. R-methotrexate procarbazine (PRIMAIN) - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5383936/ 

5. RW studies: Andy Evens 500 pts >60 - https://pubmed.ncbi.nlm.nih.gov/36965007/ 

6. LYSA PRECIS study https://pubmed.ncbi.nlm.nih.gov/35834762/ 

7. IELSG43 study Lugano (https://onlinelibrary.wiley.com/doi/full/10.1002/hon.3163_15)  and ASH late breaking 2022 (https://ashpublications.org/blood/article/140/Supplement%202/LBA-3/493427/Effects-on-Survival-of-Non-Myeloablative) 

8. Secondary CNS lymphoma 134 pts UK PR vs CR autograft - https://pubmed.ncbi.nlm.nih.gov/36300776/ 

9. “How I Treat secondary CNS involvement by aggressive lymphomas?”-

     https://pubmed.ncbi.nlm.nih.gov/37702537/

1. Phase II OPTIMUM (MUKnine) trial in ultra-high-risk myeloma and PCL:

https://pubmed.ncbi.nlm.nih.gov/37315268/

2. Meta-analysis of >2500 patients with chromosome 1q21 abnormalities:

https://pubmed.ncbi.nlm.nih.gov/34092058/

3. Predicting ultra-high risk myeloma by molecular profiling (including SKY92 GEP signature):

https://pubmed.ncbi.nlm.nih.gov/32157174/

4. French data on adverse prognostic impact of del(1p32):

https://pubmed.ncbi.nlm.nih.gov/36375118/

5. S1211 study: The first high-risk enrichment RCT in myeloma (VRD vs Elo-VRD):

https://pubmed.ncbi.nlm.nih.gov/33357482/

6. Outcome of “double-hit” patients in MASTER and Dara-VRD arm of GRIFFIN trial:

https://ashpublications.org/blood/article/140/Supplement%201/10144/488521

7. Impact of Auto-Transplant on decreasing MRD burden in high-risk myeloma (including double-hits):

https://pubmed.ncbi.nlm.nih.gov/35731911/

8. Preliminary results from GMMG-CONCEPT trial in high-risk myeloma:

https://pubmed.ncbi.nlm.nih.gov/34732857/

1. “How I Treat Peripheral T-cell Lymphoma?”:
https://pubmed.ncbi.nlm.nih.gov/24615779/

2. ECHELON-2- RCT of CHOP vs BV-CHP in CD30-positive peripheral T-cell lymphomas:
https://pubmed.ncbi.nlm.nih.gov/34921960/

3. Ro-CHOP Phase III study (LYSA): Romidepsin-CHOP vs CHOP in peripheral T-cell lymphoma:
https://pubmed.ncbi.nlm.nih.gov/34843406/

4. RCT of autologous vs allogeneic HSCT as part of 1st line therapy in poor risk peripheral T-cell lymphoma:
https://pubmed.ncbi.nlm.nih.gov/33512419/

5. A phase 2 biomarker-driven study of ruxolitinib in T-cell lymphomas:
https://pubmed.ncbi.nlm.nih.gov/34653242/

6. JACKPOT8 study: Selective JAK1 inhibitor in relapsed/refractory peripheral T-cell lymphoma:
https://ash.confex.com/ash/2020/webprogram/Paper134650.html

1. CCUS and risk of transformation to myeloid neoplasms:
https://www.sciencedirect.com/science/article/pii/S0006497121013471

2. Prediction of risk for myeloid neoplasms in clonal hematopoiesis:

https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200310

3. CHRS risk score:

http://www.chrsapp.com

4. Germline predisposition to clonal hematopoiesis: 

https://www.sciencedirect.com/science/article/abs/pii/S0145212623006094?via%3Dihub

https://www.nature.com/articles/s41586-020-2819-2

5. Cancer therapy shapes the fitness landscape of clonal hematopoiesis:

https://www.nature.com/articles/s41588-020-00710-0

6. Canakinumab for the prevention of progression to cancer in patients with Clonal Cytopenias of Unknown Significance, IMPACT Study:

https://clinicaltrials.gov/study/NCT05641831?cond=CCUS%20Clonal%20Cytopenia%20of%20Undetermined%20Significance&rank=3

7. Ivosidenib in patients with CCUS and mutations in IDH1:

https://classic.clinicaltrials.gov/ct2/show/NCT05030441

https://sites.wustl.edu/pimm/

• How I treat PNH: https://pubmed.ncbi.nlm.nih.gov/33512400/
• Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia: https://pubmed.ncbi.nlm.nih.gov/37084383/
• Pegcetacoplan versus eculizumab in PNH: a) https://pubmed.ncbi.nlm.nih.gov/33730455/  b) https://pubmed.ncbi.nlm.nih.gov/35349667/
• Phase 2 study of danicopan (factor d inhibitor) in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab: https://pubmed.ncbi.nlm.nih.gov/34314483/
• Complement and prothrombotic state: https://pubmed.ncbi.nlm.nih.gov/34415298/

Link for our Blood Cancer Talks Survey: https://bit.ly/BCTS

Here are the key trials we discussed:

1. RATHL Trial (PET-adapted treatment of Advanced Hodgkin’s Lymphoma):

https://pubmed.ncbi.nlm.nih.gov/27332902/

2. S0816 (PET-adapted treatment of Advanced Hodgkin’s Lymphoma):

https://pubmed.ncbi.nlm.nih.gov/27069074/

3. ECHELON-1 (Replacing Bleomycin by Brentuximab Vedotin in Advanced Hodgkin’s Lymphoma):

https://pubmed.ncbi.nlm.nih.gov/29224502/

https://pubmed.ncbi.nlm.nih.gov/35830649/

4. BREACH (BV-AVD vs ABVD for Early Stage Unfavorable Hodgkin’s Lymphoma):

https://pubmed.ncbi.nlm.nih.gov/35867960/

5. S1826 (Nivo-AVD vs BV-AVD in Advanced Hodgkin’s Lymphoma):

https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.17_suppl.LBA4

6. FIL-ROUGE (PET-adapted ABVD vs Dose-Intensified ABVD):

https://onlinelibrary.wiley.com/doi/10.1002/hon.3163_4

7.  HD21 (BRECADD vs EBEACOPP in Advanced Hodgkin’s Lymphoma):

https://onlinelibrary.wiley.com/doi/10.1002/hon.3196_LBA5

Here are some of the key articles we discussed:

1. “How I treat refractory CRS and ICANS after CAR T-cell therapy”. 

     https://pubmed.ncbi.nlm.nih.gov/36989488/

2. CAR-HEMATOTOX score: 

    https://pubmed.ncbi.nlm.nih.gov/34166502/

3. “How I treat cytopenias after CAR T-cell therapy”.

     https://pubmed.ncbi.nlm.nih.gov/36800563/

4. Immune Effector Cell-Associated HLH-Like Syndrome (ASTCT):

    https://pubmed.ncbi.nlm.nih.gov/36906275/

5. ASTCT consensus grading for CRS and ICANS:

    https://pubmed.ncbi.nlm.nih.gov/30592986/

6. Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy:

    https://pubmed.ncbi.nlm.nih.gov/35696759/

7. Modified EASIX score for predicting CRS and neurotoxicity:

    https://pubmed.ncbi.nlm.nih.gov/34432870/

1. For a primer on CAR T-cell therapy, listen to our episode aired on July 22nd 2022 with Dr. Surbhi Sidana: https://share.transistor.fm/s/efc4acf9

2. RCTs of BCMA CAR T-cell Therapy in Early Relapsed Multiple Myeloma:

a) KarMMa-3 (ide-cel): https://pubmed.ncbi.nlm.nih.gov/36762851/

b) CARTITUDE-4 (cilta-cel): https://pubmed.ncbi.nlm.nih.gov/37272512/

3. Clinical trials of GPRC5D CAR T-cell therapy in multiple myeloma:

a) MCARH109 (MSKCC Trial): https://pubmed.ncbi.nlm.nih.gov/36170501/

b) POLARIS Trial: https://pubmed.ncbi.nlm.nih.gov/36725117/

3. Phase 1 UNIVERSAL trial of ALLO-715 in Multiple Myeloma:
https://pubmed.ncbi.nlm.nih.gov/36690811/

4. Anti BCMA/CD19 CAR T-cells with IMiD maintenance therapy in myeloma:
https://pubmed.ncbi.nlm.nih.gov/36413381/

1. Teclistamab (MajesTEC-1 trial): https://pubmed.ncbi.nlm.nih.gov/35661166/

2. Correlative analysis from MajesTEC-1 trial: https://ashpublications.org/blood/article/140/Supplement%201/241/487619

3.  Talquetamab (MonumenTAL-1 trial): https://pubmed.ncbi.nlm.nih.gov/36507686/

4. Phase 1 trial of fixed-duration cevostamab: 

https://ashpublications.org/blood/article/140/Supplement%201/4415/492339

5. Phase 1 trial of ABBV-383: https://pubmed.ncbi.nlm.nih.gov/36029527/

6. Paper summarizing infections with different bispecific antibodies in myeloma: https://pubmed.ncbi.nlm.nih.gov/36716411/

1. ASH choosing wisely:
 https://www.hematology.org/education/clinicians/guidelines-and-quality-care/choosing-wisely

2. International Consensus Classification (ICC):
 https://pubmed.ncbi.nlm.nih.gov/35767897/

3. WHO classification 2022:
 https://pubmed.ncbi.nlm.nih.gov/35732829/

4. IPSS-M:
 https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200008

5. Romiplostim in MDS:
 https://pubmed.ncbi.nlm.nih.gov/29396092/

6. Low-dose decitabine vs. low-dose azacItidine in lower-risk MDS:
 https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200034

7. Luspatercept in MDS:
 https://www.nejm.org/doi/full/10.1056/nejmoa1908892

8. Lenalidomide in MDS: 

https://ascopubs.org/doi/10.1200/JCO.2015.66.0118

https://pubmed.ncbi.nlm.nih.gov/21753188/

9.Iron chelation therapy in MDS: 

https://pubmed.ncbi.nlm.nih.gov/32203980/

2:11 How to diagnose mantle cell lymphoma (MCL)?

6:51 Clinical manifestations of mantle cell lymphoma

7:52 How to manage leukemic variant of MCL? 

12:08 Is Watch-and-Wait reasonable in selected cases of nodal MCL with low Ki-67?

17:21 Overview on treatment of newly diagnosed MCL

19:03 Are all cytarabine-based regimens for MCL created equally?  

RCT of Autologous Transplantation in MCL: https://pubmed.ncbi.nlm.nih.gov/15591112/

21:39 In a world without upfront ibrutinib access as per TRIANGLE trial, do all fit patients with MCL need consolidation with auto-transplant? 

22:44 How to approach unfit patients with newly diagnosed MCL? 

RCT of bortezomib-based therapy (VR-CAP) in newly diagnosed MCL: https://pubmed.ncbi.nlm.nih.gov/25738670/

24:57 SHINE Trial-RCT of Ibrutinib plus BR in newly diagnosed MCL: https://pubmed.ncbi.nlm.nih.gov/35657079/

30:38 TRIANGLE Trial-RCT of upfront ibrutinib with or without auto-transplant in newly diagnosed MCL:

https://ashpublications.org/blood/article/134/Supplement_1/2816/423504

43:01: Does Allo-Transplant have any role in MCL?

44:08: What are the likely next breakthroughs in newly diagnosed MCL space? 

Here are some of the sections discussed in this episode:

03:33 Diagnostic workup of myeloma in LMICs

15:46 Induction therapy for new diagnosed transplant-eligible myeloma

27:17 Early Transplant vs Delayed Transplant in the Context of LMICs

33:11 Maintenance therapy 

37:27 Management of relapsed myeloma

Affordability of novel drugs in myeloma: https://pubmed.ncbi.nlm.nih.gov/29461639/

45:30 Clinical Trials in LMICs. Is industry exploiting patients in LMICs?

Article by Dr. Gómez-De León in Lancet Haematology:  https://pubmed.ncbi.nlm.nih.gov/36174637/

1. Risk stratification of PMF:
MIPSS70 Score: http://www.mipss70score.it
https://ascopubs.org/doi/full/10.1200/JCO.2017.76.4886

Genetically inspired prognostic scoring system (GIPSS):
https://www.nature.com/articles/s41375-018-0107-z

Type 1 CALR mutation:
https://ashpublications.org/blood/article/124/15/2465/33454

MYSEC-PM:
http://www.mysec-pm.eu
https://www.nature.com/articles/leu2017169

2. Treatment of PMF with JAK inhibitors
https://pubmed.ncbi.nlm.nih.gov/36680511/

Momelotinib:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)02036-0/fulltext

Pacritinib : https://ashpublications.org/blood/article/140/Supplement%201/1518/490663
https://jamanetwork.com/journals/jamaoncology/fullarticle/2674384

Fedratinib:
https://onlinelibrary.wiley.com/doi/10.1111/bjh.18284

3. Allogeneic Transplant in PMF
https://ashpublications.org/hematology/article/2021/1/453/482995

Black African-American patients with primary myelofibrosis
https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2022009611/494460

4. Imtelestat in PMF
https://www.nejm.org/doi/full/10.1056/NEJMoa1310523

https://ashpublications.org/blood/article/140/8/828/485274

2. Risk-Stratification Models in SMM:

Mayo 2018 model: https://pubmed.ncbi.nlm.nih.gov/29895887/

PETHEMA (Spanish) model: https://pubmed.ncbi.nlm.nih.gov/17576818/

PANGEA model: https://pubmed.ncbi.nlm.nih.gov/36858677/

IMWG SMM model: https://pubmed.ncbi.nlm.nih.gov/33067414/

3. QuiRedex RCT (Lenalidomide-Dexamethasone vs Observation in High-Risk SMM):

https://pubmed.ncbi.nlm.nih.gov/36067617/

4. ECOG E3A06 RCT (Lenalidomide vs Observation in SMM):

https://pubmed.ncbi.nlm.nih.gov/31652094/

5. Intensive Treatment in High-Risk Smoldering Multiple Myeloma:

GEM-CESAR: https://ashpublications.org/blood/article/140/Supplement%201/292/490268

ASCENT: https://ashpublications.org/blood/article/140/Supplement%201/1830/492739

6. Current Clinical Trial Landscape in Smoldering Myeloma:

https://pubmed.ncbi.nlm.nih.gov/34114943/

7. How Light Chain Proteinuria Modulates Risk of Progression in Patients with sFLC ratio>100 as the only Myeloma-Defining Event? 

https://pubmed.ncbi.nlm.nih.gov/35190659/

1. Review article on aplastic anemia: 

https://www.nejm.org/doi/10.1056/NEJMra1413485

2. RCTs testing whether addition of cyclosporine to ATG improves outcomes in aplastic anemia:

https://www.nejm.org/doi/10.1056/NEJM199105093241901

https://www.sciencedirect.com/science/article/pii/S0006497120489748

3. RCT testing horse versus rabbit ATG in aplastic anemia:

https://www.nejm.org/doi/full/10.1056/nejmoa1103975

4. Single-arm study of eltrombopag in addition to standard immunosuppressive therapy in aplastic anemia: 

https://www.nejm.org/doi/10.1056/NEJMoa1613878

5. Long-term follow up of patients treated with immunosuppressive therapy and eltrombopag:

https://ashpublications.org/blood/article/139/1/34/476916

6. RACE Trial: Standard immunosuppressive therapy +/- eltrombopag in aplastic anemia:

https://www.nejm.org/doi/10.1056/NEJMoa2109965

7. Clinical and molecular determinants of clonal evolution in patients with aplastic anemia:

https://ascopubs.org/doi/abs/10.1200/JCO.22.00710

https://ash.confex.com/ash/2022/webprogram/Paper159962.html

2.     Phase III Dauno-Double Trial

https://ash.confex.com/ash/2022/webprogram/Paper157126.html

3.     Reduced venetoclax exposure: 

https://ash.confex.com/ash/2022/webprogram/Paper165464.html

4.    Menin Inhibitors in AML 

https://ash.confex.com/ash/2022/webprogram/Paper164849.html

https://ash.confex.com/ash/2022/webprogram/Paper167412.html

5.    Imetelstat in MDS: IMerge Phase 2

https://ash.confex.com/ash/2022/webprogram/Paper169050.html

6.    MOMENTUM: Momelotinib

https://ash.confex.com/ash/2022/webprogram/Paper162783.html

How I manage anemia related to myelofibrosis and its treatment regimens

 https://link.springer.com/article/10.1007/s00277-023-05126-4

1. A comprehensive review article on DLBCL:

https://pubmed.ncbi.nlm.nih.gov/33657296/

2. RCT testing CHOP vs Three Intensive Regimens in DLBCL:

https://www.nejm.org/doi/full/10.1056/nejm199304083281404 

3. RCT testing R-CHOP vs CHOP in DLBCL in older adults:

https://www.nejm.org/doi/full/10.1056/nejmoa011795 

4. RCT testing R-CHOP vs CHOP in young (MINT):

https://pubmed.ncbi.nlm.nih.gov/21940214/ 

5. PHOENIX trial: R-CHOP +/- Ibrutinib:

https://pubmed.ncbi.nlm.nih.gov/30901302/

6. R-CHOP +/- Lenalidomide (ECOG-ACRIN E1412):

https://pubmed.ncbi.nlm.nih.gov/33555941/ 

7. R-CHOP vs Pola-R-CHP (POLARIX Trial):

https://www.nejm.org/doi/full/10.1056/NEJMoa2115304

8. Comparison of 3 IPI scores in DLBCL:

https://ashpublications.org/blood/article/135/23/2041/452696

9. RCT testing R-CHOP vs Dose-Adjusted R-EPOCH (CALGB 50303):

https://ascopubs.org/doi/full/10.1200/JCO.18.01994

10. Timing of CNS Prophylaxis in DLBCL:

https://pubmed.ncbi.nlm.nih.gov/34995350/

11. RCT testing R-CHOP vs R-CHOP + Bortezomib (REMoDL-B):

https://pubmed.ncbi.nlm.nih.gov/30948276/

12. Interim PET in DLBCL? 

https://ashpublications.org/bloodadvances/article/5/9/2375/475850

13. RCTs in Limited Stage DLBCL:

CHOP x 8 vs CHOP x 3 + XRT (S8736):

https://ascopubs.org/doi/10.1200/JCO.2015.65.4582

CHOP x 4 + Rituximab x 6 vs R-CHOP x 6 (FLYER):

https://pubmed.ncbi.nlm.nih.gov/31868632/

PET-adapted therapy with R-CHOP (S1001):

https://pubmed.ncbi.nlm.nih.gov/32658627/

14.   ASH 2022 updates:

REMoDL-B update: https://ashpublications.org/blood/article/140/Supplement%201/1770/493225

Glofitamab update: https://ashpublications.org/blood/article/140/Supplement%201/1062/491024

Epcoritamab update: https://ashpublications.org/blood/article/140/Supplement%201/9443/488543

2.     Does CR really matter in the era of MRD? Landmark paper from the Spanish Group:
        https://pubmed.ncbi.nlm.nih.gov/35560160/

3.     Meta-analysis showing individual-level prognostic impact of MRD on long-term outcomes in multiple myeloma:
        https://pubmed.ncbi.nlm.nih.gov/33284948/

4.     MASTER Trial-The first trial testing MRD-adapted treatment strategy in multiple myeloma :
        https://pubmed.ncbi.nlm.nih.gov/34898239/

RATIFY clinical trial showing the addition of midostaurin (FLT3 inhibitor) to 7+3 chemotherapy for AML https://www.nejm.org/doi/full/10.1056/nejmoa1614359

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the European LeukemiaNet (ELN) https://ashpublications.org/blood/article/140/12/1345/485817/Diagnosis-and-management-of-AML-in-adults-2022

ASH 2022 abstract presenting Daunorubicin 60 Vs 90 mg/m2 https://ash.confex.com/ash/2022/webprogram/Paper157126.html

ALFA-0701. The addition of gemtuzumab ozogamicin, an anti-CD33 antibody conjugate, to the standard treatment for patients with acute myeloid leukemia

https://www.thelancet.com/article/S0140-6736(12)60485-1/fulltext

Quizartinib data presented at EHA 2022 

https://library.ehaweb.org/eha/2022/eha2022-congress/356965/harry.erba.quizartinib.prolonged.survival.vs.placebo.plus.intensive.induction.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D2233%2Amarker%3D1749%2Afeatured%3D17676

International Consensus Classification (ICC) of Myeloid Neoplasms and Acute Leukemias

https://ashpublications.org/blood/article/140/11/1200/485730/International-Consensus-Classification-of-Myeloid

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms

https://www.nature.com/articles/s41375-022-01613-1

CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia

https://ascopubs.org/doi/10.1200/JCO.2017.77.6112?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

https://www.nejm.org/doi/full/10.1056/NEJMoa2004444

https://ash.confex.com/ash/2022/webprogram/Paper159606.html

https://ash.confex.com/ash/2022/webprogram/Paper168930.html

2. What are the odds of having BMPC≥10% in a person with MGUS? IstopMM answers this question by developing a prediction model.

https://ash.confex.com/ash/2022/webprogram/Paper170166.html

Link to the model: https://istopmm.com/riskmodel/

3. RCT comparing Rd (continuous) vs Rd induction-Mel140-AHCT-R Maintenance in transplant-eligible older adults (60-75 years) with newly diagnosed multiple myeloma 

https://ash.confex.com/ash/2022/webprogram/Paper159357.html

4. Talquetamab: Phase 1/2 results from Monumental-1

https://tinyurl.com/kwn9en9m

https://www.nejm.org/doi/full/10.1056/NEJMoa2204591

5. MALDI-TOF Mass Spect for Monoclonal Free Light Chain Assessment: A promising candidate for MRD testing in AL amyloidosis

https://tinyurl.com/yrvjjruv

6. Randomized Phase IV REAL Trial (VMP vs Rd) in New Diagnosed Transplant-Ineligible Myeloma

https://tinyurl.com/bde84xuw

7. Teclistamab-Daratumumab-Lenalidomide combination in earlier lines of therapy: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study

https://ash.confex.com/ash/2022/webprogram/Paper159711.html

8. Three excellent abstracts from IstopMM:

Is MGUS associated with autoimmune disease?

https://tinyurl.com/5dafcz2w

Is isolated hypercalcemia in a person with MGUS worrisome for transformation into myeloma?

https://tinyurl.com/4tut3rea

Is MGUS associated with CKD?

https://tinyurl.com/34swvkj9

9. Outcome of patients with high-risk cytogenetic abnormalities in a secondary analysis of MASTER and Dara-VRD arm of GRIFFIN trials

https://tinyurl.com/2n78yzfh

10. Surrogacy between PFS and OS in Multiple Myeloma

https://ash.confex.com/ash/2022/webprogram/Paper163855.html

https://pubmed.ncbi.nlm.nih.gov/36495317/

CLL2-Give Trial: Updated results Obinutuzumab (G), Ibrutinib (I), and Venetoclax (Ve) triplet in Untreated Patients with CLL with 17p Deletion/TP53 Mutation (https://ash.confex.com/ash/2022/webprogram/Paper163245.html) 

AVO Trial: Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease (https://ash.confex.com/ash/2022/webprogram/Paper168003.html) 

Watch-and-Wait RCT in Follicular Lymphoma: Long-term follow-up of Phase 3 Study of Rituximab Versus a Watch and Wait Approach for Patients with Asymptomatic, Low Tumour Burden Follicular Lymphoma (https://ash.confex.com/ash/2022/webprogram/Paper156790.html)

Augment Trial: Update of Phase 3 RCT comparing Rituximab-Revlimid (R2) vs Rituximab-Placebo in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (https://ash.confex.com/ash/2022/webprogram/Paper158631.html)

TRIANGLE Study: Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma (https://ash.confex.com/ash/2022/webprogram/Paper163018.html)

Somatic alterations in Castleman Disease:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624446/
https://www.nature.com/articles/s41375-018-0323-6

Rituximab + Liposomal Doxorubicin in HHV8-positive MCD:
https://ashpublications.org/blood/article/124/24/3544/33494/Rituximab-plus-liposomal-doxorubicin-in-HIV

RCT on Siltuximab for MCD: https://pubmed.ncbi.nlm.nih.gov/25042199/

Long-term data on Siltuximab in MCD: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(19)30257-1/fulltext

• Axicabtagene ciloleucel (axi-cel) https://www.nejm.org/doi/full/10.1056/nejmoa1707447
• Tisagenlecleucel (tisa-cel) https://www.nejm.org/doi/full/10.1056/nejmoa1804980
• Lisocabtagene maraleucel (lisocel)https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31366-0/fulltext

2.  Next, we delved into the three prospective phase 3 randomized clinical trials that were conducted to define the optimal second-line treatment by comparing each of the CAR T-cell products to the current standard of care

• ZUMA-7 for axicabtagene ciloleucel https://www.nejm.org/doi/full/10.1056/NEJMoa2116133
• BELINDA for tisagenlecleucel https://www.nejm.org/doi/full/10.1056/NEJMoa2116596
• TRANSFORM for lisocabtagene maraleucel https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00662-6/fulltext

3. Then, we briefly discussed the preliminary studies of CAR-T cell therapy in front-line therapy for large B cell lymphoma

• Axicabtagene ciloleucel (axi-cel) https://www.nature.com/articles/s41591-022-01731-4

2.     Alliance Trial (Ibrutinib vs chemoimmunotherapy in older patients with untreated CLL): https://www.nejm.org/doi/full/10.1056/NEJMoa1812836

3.     E1912 (Ibrutinib vs chemoimmunotherapy in younger/fit patients with CLL): https://www.nejm.org/doi/full/10.1056/NEJMoa1817073

4.     RCT testing Acalabrutinib vs Ibrutinib (non-inferiority) in relapsed CLL: https://ascopubs.org/doi/10.1200/JCO.21.01210

5.     ELEVATE-TN Study (Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab): https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30262-2/fulltext

6.     CLL-11 trial (showed that obinutuzumab>rituximab in CLL): https://www.nejm.org/doi/full/10.1056/nejmoa1313984

7.      Initial data from German CLL-13 trial: https://ashpublications.org/blood/article/138/Supplement%201/71/477548/A-Randomized-Phase-III-Study-of-Venetoclax-Based

8.    Ventricular arrhythmia and sudden death with BTK inhibitor: https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2022016953/486090/Ventricular-Arrhythmias-and-Sudden-Death-Events?redirectedFrom=fulltext\

9.    CLL14 trial (venetoclax-obinutuzumab in untreated CLL): https://www.nejm.org/doi/full/10.1056/nejmoa1815281

10.  Extended follow-up and MRD dynamics in CLL14 trial: https://ascopubs.org/doi/10.1200/JCO.21.01181

11.   CAPTIVATE Study on fixed-duration Ibrutinib-venetoclax in newly diagnosed CLL: https://ashpublications.org/blood/article/139/22/3278/484114/Fixed-duration-ibrutinib-plus-venetoclax-for-first

12.   Ibrutinib-Venetoclax for treatment of CLL: https://www.nejm.org/doi/full/10.1056/nejmoa1900574

13.   GLOW study (Ibrutinib-Venetoclax vs Chlorambucil-Obinutuzumab): https://evidence.nejm.org/doi/abs/10.1056/EVIDoa2200006

1.     Pediatric regimen for older adolescents and young adults with ALL: CALGB 10403 https://ashpublications.org/blood/article/133/14/1548/260519/A-pediatric-regimen-for-older-adolescents-and

2.     Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: C19802 https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.27617

3.     Rituximab in B-ALL https://www.nejm.org/doi/full/10.1056/NEJMoa1605085

4.     A Phase II Trial of Blinatumomab Followed by POMP Maintenance in Older Patients with Newly Diagnosed Philadelphia Chromosome–Negative B-Cell Acute Lymphoblastic Leukemia: SWOG 1318 https://ascopubs.org/doi/abs/10.1200/JCO.21.01766

5.     Blinatumomab for MRD in adults with B-ALL https://ashpublications.org/blood/article/131/14/1522/36655/Blinatumomab-for-minimal-residual-disease-in

6.     Ph-like ALL https://www.nejm.org/doi/10.1056/NEJMoa1403088

2. HLA-DP and Risk of GVHD: https://www.nejm.org/doi/full/10.1056/NEJMoa1500140

3. Outcomes of Allogeneic Transplant with HLA-Mismatched Unrelated Donor: https://ascopubs.org/doi/10.1200/JCO.20.03502

4. Review/perspective on fundamentals of unrelated donors and cord blood units: https://ashpublications.org/blood/article/120/2/259/30405/A-perspective-on-the-selection-of-unrelated-donors

5. HLA-DQ heterodimers and HCT: https://ashpublications.org/blood/article-abstract/139/20/3009/484363/HLA-DQ-heterodimers-in-hematopoietic-cell

6. PT-Cy as GVHD prophylaxis after HCT: https://pubmed.ncbi.nlm.nih.gov/20124511/

7. Comparative outcome of MUD vs Haplo-HCT from Registry data: https://ashpublications.org/blood/article/138/3/273/475738/HLA-haploidentical-vs-matched-unrelated-donor

Pre-MEASURE Study ASCO 2022: https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.7006